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Multiparametric magnetic 
resonance imaging for quantitation 
of liver disease: a two-centre cross-
sectional observational study
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Catherine J. Kelly7, Stella Kin7, Miranda Phillips7, Amy H. Herlihy7, Timothy J. Kendall  1,8,  
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LiverMultiScan is an emerging diagnostic tool using multiparametric MRI to quantify liver disease. 
In a two-centre prospective validation study, 161 consecutive adult patients who had clinically-
indicated liver biopsies underwent contemporaneous non-contrast multiparametric MRI at 3.0 tesla 
(proton density fat fraction (PDFF), T1 and T2* mapping), transient elastography (TE) and Enhanced 
Liver Fibrosis (ELF) test. Non-invasive liver tests were correlated with gold standard histothological 
measures. Reproducibility of LiverMultiScan was investigated in 22 healthy volunteers. Iron-corrected 
T1 (cT1), TE, and ELF demonstrated a positive correlation with hepatic collagen proportionate area 
(all p < 0·001). TE was superior to ELF and cT1 for predicting fibrosis stage. cT1 maintained good 
predictive accuracy for diagnosing significant fibrosis in cases with indeterminate ELF, but not for 
cases with indeterminate TE values. PDFF had high predictive accuracy for individual steatosis grades, 
with AUROCs ranging from 0.90–0.94. T2* mapping diagnosed iron accumulation with AUROC of 
0.79 (95% CI: 0.67–0.92) and negative predictive value of 96%. LiverMultiScan showed excellent test/
re-test reliability (coefficients of variation ranging from 1.4% to 2.8% for cT1). Overall failure rates for 
LiverMultiScan, ELF and TE were 4.3%, 1.9% and 15%, respectively. LiverMultiScan is an emerging 
point-of-care diagnostic tool that is comparable with the established non-invasive tests for assessment 
of liver fibrosis, whilst at the same time offering a superior technical success rate and contemporaneous 
measurement of liver steatosis and iron accumulation.
With the increasing prevalence of chronic liver disease (CLD), particularly related to the global epidemic of 
non-alcoholic fatty liver disease (NAFLD), there is a pressing need for reliable and widely applicable meth-
ods to diagnose, stratify and monitor liver disease progression/regression that are acceptable to patients and 
cost-effective for healthcare providers1. Three independent reports have highlighted the need for the early 
detection of liver disease, including the UK Chief Medical Officer report (2011)2, the All-Party Parliamentary 
Hepatology Group Inquiry3 and the Lancet Commission in 20144. The early detection of liver disease is impor-
tant, as effective intervention can prevent progression to cirrhosis and hepatocellular carcinoma and thereby 
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reduce the economic burden of liver disease and save lives5. Despite this, existing diagnostic pathways for detec-
tion and onward referral of suspected CLD in primary care are based on traditional liver enzyme tests, which 
lack accuracy and contribute to late diagnosis, whilst staging of liver disease in secondary care and evaluation 
of drug efficacy in clinical trials remains anchored to the liver biopsy. Liver biopsy is commonly used to assess 
liver disease but has drawbacks, including sampling variability (especially in liver conditions where histological 
changes are patchy), interobserver disagreement and a potential risk of complications, including patient discom-
fort and anxiety6. A lack of robust, validated non-invasive tests has hindered drug development efforts for CLD; 
suitable alternative methods to biopsy could enable trial enrichment and/or read out as an early efficacy signal or 
surrogate endpoint.
Transient elastography (TE) (FibroScan; Echosens, Paris, France) is an established non-invasive test with good 
diagnostic accuracy for ruling out advanced fibrosis or cirrhosis (≥Metavir stage F3) and emerging prognostic 
capability7, but there is an average failure rate of 18·4%8 and cut-off values of liver stiffness for the different stages 
of liver fibrosis are not well established9. Moreover, both operator-related and patient-related factors produce sig-
nificant variations in liver stiffness measurements, limiting its potential use for monitoring disease progression10.
A range of serological tests are available for the assessment of liver fibrosis. These include simple marker pan-
els based on routine blood tests with or without clinical parameters (e.g. AST to platelet ratio index (APRI) and 
Fibrosis-4 (FIB-4) test) and more complex fibrosis-orientated marker panels (e.g. Enhanced Liver Fibrosis (ELF; 
iQur Ltd., London, UK) test and FibroTest (BioPredictive, France) which are analysed using patented algorithms. 
Although these serological tests have been validated in many chronic liver diseases and may predict clinical out-
comes11,12, they fail to classify a significant proportion of patients who fall into the ‘grey zone’ of indeterminate 
values.
Multiparametric MRI techniques have shown promise for the quantitative assessment of many chronic condi-
tions in the heart, breast, prostate and musculoskeletal system, obviating the need for invasive tissue characterisa-
tion in many patients13. In the liver, MRI proton density fat fraction (PDFF) has been shown to be highly accurate 
and reproducible for the detection and quantification of hepatic steatosis, independent of field strength, and can 
detect changes in hepatic fat as small as 1%14,15. Magnetic resonance elastography (MRE) is a phase-contrast 
MRI technique that measures liver stiffness as a surrogate of fibrosis. MRE has high accuracy for the diagnosis 
of significant liver fibrosis and cirrhosis, but it is not yet known whether it is sufficiently sensitive or dynamic for 
the longitudinal monitoring of fibrosis progression/regression16. LiverMultiScan (LMS) (Perspectum Diagnostics 
Ltd., Oxford, UK) is a proprietary, CE-marked, Food and Drug Administration (FDA) 510(k) cleared multipar-
ametric MRI methodology encompassing measurement of hepatic fibro-inflammatory injury, fat and iron17. A 
derived Liver Inflammation and Fibrosis (LIF) score has been shown in a single-centre CLD cohort to correlate 
with histological fibrosis staging, and a LIF score <2 had a NPV of 100% for a clinical outcome over a median 
follow up of 27 months18. We conducted a larger, independent, two-centre prospective validation study in an 
unselected secondary care population, with the primary objective of evaluating the ability of LMS to accurately 
measure hepatic inflammation and fibrosis, fat and iron compared to liver biopsy as the reference standard. The 
secondary objectives were to assess the performance of LMS in detecting clinically significant liver disease, to 
compare its diagnostic performance to TE and ELF, and to determine the reproducibility and repeatability of the 
technique.
Methods
Study design and population. This was a prospective two-centre validation study that represented level 
1b evidence for diagnostic test assessment19 and reported to the Standards for Reporting Diagnostic Accuracy20. 
161 unselected consecutive adult patients booked for a standard-of-care liver biopsy to investigate known or 
suspected liver disease, including patients post liver transplantation, were included. Data collection took place at 
two large tertiary UK liver centres (Queen Elizabeth Hospital Birmingham and Royal Infirmary of Edinburgh) 
between February 2014 and September 2015. Patient exclusion criteria were inability or unwillingness to give 
fully informed consent, any contraindication to MRI, and liver biopsy targeted at a focal liver lesion. Participants 
underwent contemporaneous multiparametric MRI (LMS), TE and analysis of blood biomarkers including the 
ELF test, followed by liver biopsy performed within 2 weeks of non-invasive assessments. Reference MRI data 
were also collected from 22 male and female adult healthy volunteers with no known liver disease and body mass 
index (BMI) <25 kg/m2. All study investigations were performed in a fasted state (minimum of four hours).
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki 2013 and 
Good Clinical Practice guidelines. It was approved by the institutional research departments and the National 
Research Ethics Service (14/WM/0010). The study was registered with the ISRCTN registry (ISCRTN39463479) 
and the National Institute for Health Research portfolio (15912). All patients and volunteers gave written 
informed consent.
Histological analysis of liver biopsy samples. All biopsies were reported by four independent expert 
liver histopathologists, and adequacy assessed using the definition of the Royal College of Pathologists21. All biop-
sies were staged for fibrosis using modified Ishak score (MIS) (scale 0–6; Supplementary Table 1) and collagen 
proportionate area (CPA) was calculated by morphometry after Picrosirius red staining, as previously described22. 
Liver inflammation was graded independently (none/minimal, mild, and moderate/severe) from histopathol-
ogy reports by two assessors (NM, PJE) blinded to patient characteristics and non-invasive assessment data. 
Discordance was adjudicated by a third blinded observer (TJK). Liver fat was graded 0–3 based on the percent-
age of hepatocytes in the biopsy containing a fat globule: 0 (<5%); 1 (5–32%), 2 (33–66%), and 3 (>66%)23. 
Liver iron was detected using Perls’ stain and semi-quantified using a five-tier grading system (0: no iron deposi-
tion to 4: severe iron deposition)24. As there is considerable interobserver variation in liver biopsy reporting, 45 
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randomly-selected biopsies were independently re-scored by two liver histopathologists (SH, TJK) blinded to the 
clinical data and previous pathology reports, to generate five observer pairs.
Magnetic resonance imaging and image analysis. Non-contrast MR acquisitions were performed 
with the patient in the supine position using a 3.0 tesla Siemens Verio MRI scanner system (Siemens Healthcare 
GMBH, Erlangen, Germany). MRI operators and image data assessors were blinded to the indication for liver 
biopsy and to the patients’ clinical details. MRI acquisition protocols (transverse abdominal T1 and T2* maps, 
proton density fat fraction (PDFF, %)) and image analysis were performed as previously described17, but with a 
shorter acquisition time of approximately 10 minutes. Great care was taken to optimise the acquisition protocol to 
minimise the impact of breathing motion and other artefacts. This included extensive training of the MR techni-
cians on healthy volunteers and strict quality control throughout the process. Full details of the MR protocol and 
reproducibility and repeatability studies are provided in Supplementary Methods.
Blood analysis. All patients had full blood count, coagulation profile, serum biochemistry and ELF test 
measured prior to liver biopsy.
Transient elastography. One-dimensional TE was performed using FibroScan by fully trained and certi-
fied operators, using either an M or XL probe for obese subjects to obtain ten valid readings, with a success rate 
of at least 60% and IQR <30% of the median result. XL probe was used in 81 patients (50% of study cohort). 
Controlled attenuation parameter (CAP) estimation was unavailable at the Royal Infirmary of Edinburgh.
Sample size calculation. Based on data from a previous study, the distribution of patients across the 4 
groups (Ishak 0, 1–2, 3–4 and 5–6) was 9%: 52%: 17%: 22%. The pooled value for the difference in cT1 between 
sequential groups in this data were found to be approximately 90 ms. Due to the large differences in the stand-
ard deviations across the groups, the study was powered on the “worst case” pairwise comparison, based on the 
combination of the observed standard deviation and the proportional sample size. This was between Ishak 3,4 
(SD = 57, 17% of patients) and Ishak 5,6 (SD = 90, 22% of patients).
For a comparison between these groups using an alpha level of 0.8% (i.e. 5% after adjustment for 6 compari-
sons), sample sizes of 12 and 22 for Ishak stages 3,4 and 5,6 respectively would be sufficient to detect a difference 
of 90 ms in cT1 at 80% power. Assuming that the distribution of cases was similar to the previous study, this 
meant that a sample size of 100 patients (9, 52, 17 and 22 in the four groups) would be sufficient to detect a differ-
ence between groups of 90 ms at 80% power and with 5% alpha. We targeted a total recruitment number of 150 
to account for the ~10% of biopsies that yield inadequate samples for analysis and participant non-attendance.
Statistical analysis. Repeatability of the MRI data was assessed using Bland-Altman (B-A) plots, 95% limits 
of agreement, Pearson correlation coefficients, and paired t-tests, to assess the level of bias. The mean coefficient 
of variation (CoV) was also calculated, as the average of the CoV for each patient. Interobserver agreement for 
biopsies was assessed using quadratic weighted Kappa25. Associations between continuous and ordinal variables 
were assessed using the Jonckheere-Terpstra test of trend, followed by pairwise post-hoc tests, where significant. 
For comparisons between two groups, Mann-Whitney tests were used, whilst associations between two contin-
uous variables were assessed using Spearman’s correlation coefficient (rs). Multivariable analysis was performed 
to assess the relationship between fibrosis and the diagnostic tests, after accounting for the effect of inflamma-
tion, using two-way ANOVA with inflammation, fibrosis and an interaction term as factors. TE values were 
log-transformed, prior to analysis, to improve model fit.
Diagnostic performance of tests was assessed using receiver operating characteristic (ROC) curve analyses. 
Where applicable, the areas under the ROC curves (AUROCs) were compared using the “roccomp” command in 
Stata 14 (StataCorp LP., College Station, TX), with significance tests followed by Bonferroni-adjusted post-hoc 
pairwise comparisons. Net reclassification index (NRI) was calculated as a percentage difference between cases 
correctly classified by the reference and alternative tests. Statistical analysis was performed using IBM SPSS 
Statistics for Windows version 22 (IBM Corp, Armonk, NY) and GraphPad Prism version 6.0 (GraphPad 
Software, USA). Variables were summarised as means (±standard deviation (SD)) if normally distributed and as 
medians with interquartile range (IQR) if not. A p-value of less than 0·05 was considered statistically significant.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
A total of 161 patients consented to participate and 156 were biopsied (Fig. 1). Seven biopsies (4·5%) were con-
sidered inadequate for interpretation and excluded from further analysis. Median biopsy length after processing 
was 25 mm (IQR 22–28). Interobserver agreement for histological assessment of liver fat, fibrosis and iron for 
the 45 samples that were reassessed was 71% (kappa = 0·81, almost perfect), 38% (kappa = 0·66, substantial), and 
82% (kappa = 0·24, fair), respectively (Supplementary Table 2). The kappa statistic for iron was low, relative to the 
percentage agreement, due to the fact that most patients were in the ‘no iron deposition’ group, resulting in low 
inter-case variability26.
Baseline demographic and clinical characteristics of study participants with adequate biopsies are summarised 
in Table 1.
Repeatability and reproducibility of non-invasive tests. Multiparametric MRI was well-tolerated, 
with a claustrophobia rate of only 1·9% (n = 3). Technical failure of the MRI scanner (shut-down and data loss) 
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affected 2·5% (n = 4) of patients, the remaining 96% (n = 154) all had valid cT1 and T2* data for assessment of 
fibro-inflammatory injury and liver iron, regardless of BMI. PDFF data were not acquired in the first 48 patients 
(31%). After updating the protocol, the subsequent 106 (69%) patients all had valid liver fat measurements. 
The MRI repeatability and reproducibility data are summarised in Table 2, showing significant inter-scan and 
inter-subject agreement and no evidence of a post-prandial effect.
Figure 1. Study flowchart.
Statistic
Gender (% Male) 89 (60%)
Age (years) 50 (±13)
Liver transplant 34 (23%)
Anthropometric data
Weight (kg) 85 (±19)
BMI (kg/m2) 29·7 (±6·7)
Waist:Hip Ratio
Male 0·95 (±0·08)
Female 0·86 (±0·09)
Liver Enzymes
Bilirubin (IU/L) 13 (8–18)
Alanine aminotransferase (IU/L) 58 (34–110)
Aspartate aminotransferase (IU/L) 47 (30–80)
Gamma-glutamyl transpeptidase (IU/L) 103 (52–244)
Alkaline phosphatase (IU/L) 103 (78–165)
Fibrosis stage (modified Ishak score)
0 30 (20%)
1 27 (18%)
2 24 (16%)
3 33 (22%)
4 9 (6%)
5 7 (5%)
6 18 (12%)
Final diagnosis post biopsy
NAFLD 53 (36%)
Autoimmune liver disease 25 (17%)*
Viral hepatitis 20 (13%)**
Normal 12 (8%)
Other 39 (26%)
Table 1. Baseline demographic and clinical characteristics of the 149 study participants with adequate biopsy 
data. Data reported as mean (±SD), median (IQR), or n (%), as applicable. *13 AIH, 3 PBC, 3 PSC, 6 overlap 
syndromes and autoimmune cholangiopathies. **13 patients post-transplant.
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Subsequent to this study, we have performed an independent clinical evaluation of the test-retest perfor-
mance of LMS using both healthy controls and patient volunteers (n = 46) (unpublished data). Consistent with 
the results reported in this manuscript, the 95% limits of agreement for the mixed healthy control/patient popu-
lation was −60.5 ms to 49.5 ms with a bias (±SD) of −5.5 ms (±28.1 ms) and a mean CoV of 2.0%. The B-A plot 
showed no evidence that the test-retest performance is different in patients vs. controls.
The TE failure rate was 15% (n = 24) overall, 7·7% for patients with BMI < 30 and 25% for patients with 
BMI ≥ 30. One patient was unsuitable for TE due to the presence of ascites detected by MRI. Three patients (1·9%) 
had unavailable ELF data.
Assessment of hepatic fibro-inflammatory injury by multiparametric MRI, TE and ELF test. 
cT1 (rs = 0·33), ELF (rs = 0·41) and TE (rs = 0·52) were all positively associated with liver fibrosis as assessed by CPA 
(all p < 0.001). ROC curve analysis using only valid measurements (Table 3) found no significant difference between 
the accuracy of the three tests for identifying patients with any (MIS ≥ 1) fibrosis (p = 0·085). However, TE was supe-
rior to both cT1 and ELF for identification of patients with moderate-severe (MIS ≥ 3) fibrosis (p = 0·022, 0·005), 
and severe (MIS ≥ 5) fibrosis (p = 0·003, < 0·001). Following exclusion of post-liver transplant patients, TE retained 
superiority for identification of only severe (MIS ≥ 5) fibrosis (p = 0.002, 0.029) (Supplementary Table 3).
On multivariable analysis, after accounting for the effect of inflammation, ELF (p = 0·011), cT1 (p = 0·002) 
and TE (p < 0·001) remained significantly associated with fibrosis stage (Fig. 2). In addition, ELF was found to 
increase with the level of inflammation (p < 0.001), with values being 0·6 (SE = 0·3, p = 0·027) higher in patients 
with mild inflammation, and 1·2 (SE = 0·3, p < 0·001) higher in patients with moderate/severe inflammation, 
cT1 T2* PDFF
Scan-Rescan
Mean CoV (%) 2·1 2·6 8·8
Pearson’s r (95% CI) 0·73 (0·19–0·93) 0·99 (0·97–1·0) 0·99 (0·96 to 1·0)
Bland-Altman Analysis‡
Bias (mean (±SD)) −13 (35) −0·05 (0·83) −1·1 (2·3)
p-value† 0·285 0·862 0·250
95% limits of agreement −81 to 56 −1·7 to 1·6 −5·7 to 3·5
10 week time course
Mean CoV (%) 2·8 6·6 NA#
Fasted-Fed
Mean CoV (%) 1·40 7·4
NA##
Pearson’s r (95% CI) 0·94 (0·82–0·98) 0·90 (0·71–0·97)
Bland-Altman Analysis
  Bias (mean±SD) −3 (22) 1·4 (2·9)
  p-value† 0·606 0·070
  95% limits of agreement −46 to 40 −4·2 to 7·1
Table 2. Repeatability of multiparametric MRI. #All healthy volunteers had PDFF of < 2%; ##only 2 healthy 
volunteers had PDFF > 2%. †From a paired t-test, to test for significant bias. ‡See Supplementary Fig. 1 for B-A 
plots.
Fibrosis 
stage (MIS)
Multiparametric MRI (n = 142) ELF test (n = 147)
TE 
(n = 125)
p-value*
AUROC 
(95% CI)
Cut off levels
Se Sp PPV NPV
AUROC 
(95% CI)
Cut off 
levels Se Sp PPV NPV
AUROC 
(95% CI)cT1 (ms) LIF
≥1 0·72 (0·61–0.83) 800 1 86 38 84 41
0·79  
(0·71–0·88) 7·7 92 24 83 44
0·83 
(0·74–0·92) 0.085
≥3 0·72  (0·63–0·80) 875 2 88 51 60 83
0·70 
(0·61–0·78) 9·8 49 77 65 64
0·84 
(0·76–0·91)  < 0.001
≥5 0·72 (0·64–0·81) 950 3 71 64 28 92
0·68 
(0·57–0·79) 11·3 19 91 31 84
0·86 
(0·79–0·93)  < 0.001
Table 3. Diagnostic accuracy of multiparametric MRI, ELF and TE in detecting any, moderate-to-severe and 
severe liver fibrosis. Se, sensitivity; Sp, specificity; NPV, negative predictive value; PPV, positive predictive value. 
All AUROCs were significant at p < 0·001. *p-values comparing the AUROCs of multiparametric MRI vs. 
ELF vs. TE for the n = 117 patients with data available for each measure. Significant comparisons (bold) were 
followed by post-hoc pairwise comparisons, the p-values of which were Bonferroni corrected to account for 
multiple comparisons. These comparisons found TE to be significantly superior to both multiparametric MRI 
and ELF test in the detection of MIS ≥ 3 (p = 0.022, 0.005) and MIS ≥ 5 (p = 0.003, < 0.001). **TE cut off levels 
not included as they are specific to aetiology of liver disease.
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compared to those with no/minimal inflammation. No significant interaction effect between inflammation and 
fibrosis was detected for ELF (p = 0·641).
For TE, a significant interaction effect between inflammation and fibrosis was detected (p = 0·050). As shown 
in Fig. 2, the increase in TE with fibrosis was similar for patients in the no/minimal and mild inflammation 
groups. However, for patients with moderate/severe inflammation, the increase in TE by MIS was not observed, 
with a geometric mean TE of 13·3 (95% CI: 5·4–9·2) for MIS 1–2 and 17·5 (95% CI: 13·3–23·1) in MIS 5–6. A 
similar interaction effect was also observed in the analysis of cT1 (p = 0·050), with the magnitude of the increase 
with MIS becoming smaller with increasing levels of inflammation.
Assessment of liver fat and iron by multiparametric MRI. There was a strong positive correlation 
between increasing histological fat (Brunt grade) and PDFF (rs = 0·79, p < 0·001, n = 98) (Supplementary Fig. 2a). 
PDFF had excellent predictive accuracy for individual grades of steatosis, with AUROCs ranging from 0.90–0.94 
(Supplementary Fig. 2a and Supplementary Table 4).
There was a negative correlation between liver iron content and T2* (rs = −0·34, p < 0·001, n = 142), and 
a significant difference in T2* between patients with and without histological iron deposition (p < 0·001) 
(Supplementary Fig. 2b). In distinguishing patients with stainable iron from those without, T2* had an AUROC 
of 0·79 (95% CI 0·67–0·92, p < 0·001). At a cut-off of 18 ms, sensitivity was 83%, specificity 63%, PPV 25% and 
NPV 96%.
Comparative performance of non-invasive tests to detect clinically significant liver disease. 
Median (IQR) cT1 and LIF score for the 22 healthy volunteers was 761 (741–811) ms and 0.76 (0.60–1.15) respec-
tively, which was similar to the median cT1 and LIF score in patients with no evidence of liver disease on liver 
biopsy (cT1 787 (757–866) ms and LIF 0.91 (0.71–1.88), both p = 0.276). All non-invasive measurements were 
significantly different between patients with normal liver histology or simple steatosis and those with fibrosis and/
or inflammation on biopsy (p < 0·0001 for all tests) (Table 4). To compare diagnostic accuracy between tests, a 
complete case analysis was performed on the subgroup of patients for whom adequate liver biopsy, cT1, TE and 
ELF measurements were all available. No significant difference was detected between the predictive accuracy of 
the three tests for the differentiation between normal biopsies/steatosis and the presence of any degree of inflam-
mation and/or fibrosis (p = 0.500, n = 117, Supplementary Fig. 4 and Table 4). Following exclusion of post-liver 
Figure 2. Multivariable analysis of inflammation and fibrosis. Plotted values are arithmetic means for cT1 and 
ELF score, and geometric means for TE, with the error bars representing 95% confidence intervals. Only one 
patient had no/minimal inflammation and a modified Ishak score (MIS) of 0, hence this point was excluded 
from the plots.
Normal + simple 
steatosis
Inflammation and/or 
fibrosis
AUROC 
(95% CI) p-value
Diagnostic test 
failure rate
All patients
cT1/LIF 23 119 0.76 (0.66–0.88)  < 0.001 4.3%
ELF 23 124 0.80 (0.72–0.89)  < 0.001 1.9%
TE 21 104 0.83 (0.74–0.91)  < 0.001 15%
Excluding post-transplant
cT1/LIF 13 89 0.89 (0.83–0.95)  < 0.001 6.1%
ELF 19 94 0.77 (0.67–0.88)  < 0.001 1.7%
TE 17 79 0.85 (0.76–0.93)  < 0.001 16.5%
Table 4. Diagnostic accuracy of multiparametric MRI, ELF and TE in detecting clinically significant liver 
disease, with and without post-liver transplant patients included.
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transplant patients, cT1 showed superior predictive accuracy differentiating between these groups, although sta-
tistical significance was not achieved (p = 0.063, Table 4).
Comparative performance of non-invasive tests to detect significant liver fibrosis. Diagnosis of 
significant (moderate/severe) liver fibrosis identifies patients requiring close clinical follow up (including variceal 
and hepatocellular carcinoma surveillance in cirrhotics) and those most in need of therapeutic interventions to 
prevent progression of liver disease and/or decompensation, including participation in clinical trials. In order to 
compare the predictive accuracy of the tests in the context of clinical use, a set of net reclassification index (NRI) 
analyses were performed (Table 5). These compared the prognostic ability, with regards to significant liver fibro-
sis, between cT1, TE, ELF and the combination of TE and FIB-4, which was chosen as a ‘conventional diagnostic 
test’ that incorporates a non-patented serum score and TE. Based on the cut offs used, we found no significant 
difference between cT1 and either TE or ELF. The combination of TE/FIB-4 had poor predictive accuracy, with 
TE alone performing significantly better (p = 0.007).
We performed a subgroup analysis that excluded post liver transplant patients (Supplementary Table 5), which 
found no significant difference between cT1 and either TE or ELF. As per the analysis of the whole cohort, predic-
tive accuracy of the TE/FIB-4 combination was poor, and inferior to TE alone.
Subgroup analyses were also performed to assess the predictive accuracy of cT1 in those cases with indetermi-
nate ELF and TE values. For those with indeterminate ELF (>7.7 and ≤9.8, n = 76), cT1 maintained good predic-
tive accuracy for diagnosing significant fibrosis, as in the whole cohort (Table 6). However, cT1 was not found to 
be predictive of significant fibrosis in the n = 36 patients with borderline TE (>7 and ≤13).
Discussion
Validated non-invasive tools for the diagnosis, stratification and monitoring of liver disease are an urgent require-
ment to streamline clinical care pathways and facilitate drug development. One of the emerging imaging-based 
technologies is LMS, a rapid non-contrast multiparametric MRI scan quantifying hepatic fibro-inflammatory 
injury, fat and iron. Here we describe the first independent validation study of LMS where, critically, its perfor-
mance was also evaluated alongside other commonly used non-invasive biomarkers.
MRI scanners are available in most UK hospitals and, in contrast to MRE, LMS can be implemented on any 
modern clinical 1.5 or 3.0 tesla MR scanner with no additional hardware requirements. MRI with LMS is not 
contraindicated in patients with metal implants, as any modern (within the last 20 years) implants are almost 
100% non-ferrous.
Crucially for an emerging diagnostic test, we showed that MRI with LMS had excellent repeatability and 
reproducibility (immediate test-retest and repeated over 10 weeks). Additionally, unlike other non-invasive imag-
ing tests, quantification of fibro-inflammatory injury was unaffected by post-prandial state, potentially increasing 
ease of use and patient acceptability by avoiding pre-scan fasting. Immediate test-retest repeatability of LMS has 
also been confirmed in a mixed healthy volunteer/patient cohort (unpublished data).
We have validated, in a diverse unselected secondary care population, that LMS has good diagnostic accuracy 
for detecting fibro-inflammatory injury, fat and iron in the liver across a range of disease severity and aetiology 
when compared to the current imperfect ‘gold standard’ of liver biopsy. We acknowledge the unavoidable patient 
selection bias introduced by the requirement for liver biopsy, as well as the need for further studies to define 
applicability of LMS in other patient groups.
Tests Total 
N Reclassified Cases**
Cases Correctly Classified by
NRI p-valueReference Alternative Reference Test Alternative Test
ELF (>9.8) cT1 (>875 ms) 140 63 29 34 0.08 0.615
TE (>13) cT1 (>875 ms) 119 53 26 27 0.02 1.000
TE (>13) ELF (>9.8) 123 25 16 9 −0.28 0.230
TE/FIB-4* cT1 (>875 ms) 118 64 26 38 0.19 0.169
TE/FIB-4* ELF (>9.8) 122 28 12 16 0.14 0.572
TE/FIB-4* TE (>13) 124 15 2 13 0.73 0.007
Table 5. Net reclassification indices for the diagnosis of fibrosis stage≥3. *Cases with both TE > 13 and 
FIB-4 > 2.67 were treated as positive tests. **The number of cases classified differently by the two tests. p-values 
are from McNemar’s test, and bold values are significant at p < 0.05.
Inclusion Criteria N AUROC for cT1 (95% CI) p-Value Se Sp PPV NPV
ELF > 7.7 and ≤9.8 76 0.70 (0.58–0.82) 0.003 84 55 57 83
TE > 7 and ≤13 36 0.55 (0.33–0.76) 0.657 96 31 71 80
Table 6. Diagnostic accuracy of cT1 in detecting fibrosis stage ≥3 in cases with borderline ELF and TE. Se, 
sensitivity; Sp, specificity; NPV, negative predictive value; PPV, positive predictive value. Bold p-values are 
significant at p < 0.05.
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Based on the ROC analysis (Table 3), TE was superior to both multiparametric MRI and ELF test in the detec-
tion of moderate and severe fibrosis, whilst all three non-invasive tests were comparable for the detection of any 
fibrosis. Both for TE and LMS, a significant interaction effect between inflammation and fibrosis was detected. As 
T1 relaxation time is influenced by the presence of inflammation27 and liver fat28, a more nuanced understanding 
of the individual and combined effects of fibrosis, inflammation, fat and iron on T1 relaxation time in different 
aetiologies of liver disease is required to refine the interpretation of LMS. However, the multiparametric MRI 
sequence is ideally suited to correct for these distinct histological variables.
LMS, ELF and TE had comparable predictive accuracy for the differentiation between normal biopsies/stea-
tosis and the presence of any degree of inflammation and/or fibrosis. On a post hoc analysis, we have identified 
that liver transplantation may influence the diagnostic performance of cT1 in detecting significant liver disease, 
with a substantial but not significant improvement in diagnostic accuracy observed (AUROC 0.89 vs. 0.76) when 
post-transplant patients were excluded. To investigate this further, a prospective multicentre trial comparing the 
accuracy of LMS against a liver biopsy in the assessment of liver transplant recipients is ongoing (NCT03165201).
Following net reclassification analysis, cT1 was comparable to TE and ELF in diagnosing significant liver 
fibrosis, when using the proposed cut off of 875 ms. Moreover, our analysis suggested that cT1 could be used to 
increase the diagnostic yield in indeterminate ELF cases, although this was not true for indeterminate TE cases. 
These findings have particular relevance in NAFLD patients, in whom National Institute for Health and Care 
Excellence (NICE) guidance recommends the ELF test for the identification of liver fibrosis29, and where TE fail-
ure rates are highest due to obesity, currently necessitating further evaluation via alternative imaging modalities 
such as acoustic radiation force impulse (ARFI) imaging, shear wave elastography or by liver biopsy. A recent 
decision analytic model for NHS patients with suspected NAFLD suggested that inclusion of LMS either as an 
adjunct to or replacement for TE in clinical care pathways may lead to cost savings by reducing the number of 
liver biopsies30.
LMS demonstrated 98.1% technical success rate even in obese subjects, which compares favourably with the 
average TE success rate of 85%, even with the XL probe. The high technical success rate of LMS has been corrob-
orated in 5000 subjects included in the UK Biobank cohort (96.4% for PDFF estimation)31.
In contrast to the previous study by Banerjee et al.17, we used the well-established modified Dixon method 
for PDFF to quantify liver fat, a technique that is widely applicable across different MRI platforms and is highly 
correlated with MR spectroscopy and also hepatic triglyceride levels15. Additionally, MRI-PDFF is more reliable 
than Fibroscan Controlled Attenuation Parameter in obese individuals32. We have recently reported a subgroup 
analysis of multiparametric MRI in NAFLD patients from our study cohort33.
LMS also incorporates gold standard MRI assessment of liver iron34,35 performed with a high degree of accu-
racy (sensitivity and NPV of 83% and 96% respectively), with potential application in the diagnosis and monitor-
ing of hereditary and acquired conditions leading to iron overload.
The optimal LMS cut-off points for stratification of different CLD stages will require further investigation in 
different research settings and may be disease-specific. However, based on the application of LMS MRI in the UK 
Biobank cohort, a LIF score of ≤0.82 (95% CI 0.72–0.95) has been validated as a normal value for the UK popu-
lation. Thus, in a general population setting, a LIF score of ≤1 with its high sensitivity (86%) would strongly indi-
cate the absence of significant fibro-inflammatory liver disease, allowing identification of low-risk patients who 
could be spared further investigations and unnecessary follow-up. In contrast, a LIF cut-off >2 identified CLD 
patients with an increased risk of clinical outcomes18 and could therefore potentially be used to enrich trial pop-
ulations prior to enrolment in interventional studies, or as a clinically meaningful surrogate endpoint. Given that 
emerging treatments (and potential combination regimens) for CLD may modulate fat and fibro-inflammatory 
components of liver injury to a variable extent, quantitative multiparametric MRI assessments may be well suited 
for drug development, especially in NASH.
In this first “in-the-field” study, LMS demonstrated good diagnostic accuracy for detecting fibro-inflammatory 
injury, fat and iron in the liver across a range of disease severity and aetiology and with excellent repeatability and 
reproducibility. Its diagnostic performance was comparable to existing well-validated non-invasive biomarkers. 
Overall, our findings support the further development and refinement of multiparametric MRI technology for 
assessment of liver disease.
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